RE:RE:Need trials underway"Big pharmaceutical companies have entered the market through several operations in the past years. Canadian research and development (R&D) company Avicanna became a resident company at Jonhson & Johnson's JLabs in Toronto in 2017. One year later, Canadian Tilray went global through an agreement with Swiss pharmaceutical company Novartis AG to develop and distribute its medical cannabis products in legal jurisdictions worldwide. In May 2021, global biopharmaceutical company Jazz Pharmaceutical completed the acquisition of GW Pharmaceuticals, the developer of Epidiolex, the first FDA-authorized CBD medicine for treating children with Lennox-Gastaut and Dravet syndromes. Like Big Tobacco companies, Big Pharma's interest in the medical cannabis industry grows with the space's fast-evolving cannabinoids industry. R&D on cannabinoids is achieving exciting results in the treatment application. For this reason, it is expected to see further involvement of pharmaceutical companies in the medical cannabis industry in the following years."